Dr. Freudenreich works as an attending psychiatrist and resident supervisor in the MGH Schizophrenia Program at the Freedom Trail Clinic in the Erich Lindemann Mental Health Center. His academic interest is in the area of optimal psychopharmacological treatment for schizophrenia, including clozapine for refractory psychosis, early course schizophrenia, the role of medical morbidity in schizophrenia, the integration of medicine and psychiatry, and treatment adherence. In addition to his clinical and clinical trial expertise in schizophrenia, Dr. Freudenreich provides psychiatric consultations for medically complex patients with serious mental illness or diagnostically difficult cases with psychosis.  He is a deputy editor for the journal Psychosomatics.  He has published extensively in his areas of interest and he wrote a handbook on psychotic disorders.  Dr. Freudenreich is an active teacher who lectures regularly at national meetings and at his home institution.  At MGH, he is the course director for the Department of Psychiatry’s monthly Morbidity and Mortality conference.

 Dr. Freudenreich received his medical degree from the University of Heidelberg in Germany. He completed his psychiatric residency at UMDNJ/Rutgers in New Jersey. Additional training included a 2-year fellowship at Duke University in psychiatric research and a 1-year fellowship at MGH in psychosomatic medicine. The Duke fellowship exposed him to clinical trials methodology as well as sophisticated psychopharmacology of schizophrenia. For his involvement in research and medical education, he has received fellowships from the Society of Biological Psychiatry, from the Academy of Psychosomatic Medicine, and the American Association of Directors of Psychiatric Residency Training.